(2R,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (BioDeep_00000175802)
human metabolite blood metabolite
代谢物信息卡片
(2R,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
化学式: C21H25ClO6 (408.134)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl
InChI: InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Jiwen Jim Liu, TaeWeon Lee, Ralph A DeFronzo. Why Do SGLT2 inhibitors inhibit only 30-50\% of renal glucose reabsorption in humans?.
Diabetes.
2012 Sep; 61(9):2199-204. doi:
10.2337/db12-0052. [PMID: 22923645] - Gábor Simonyi. [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Orvosi hetilap.
2012 May; 153(18):695-701. doi:
10.1556/oh.2012.29351. [PMID: 22547464] - R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
International journal of clinical practice.
2012 May; 66(5):446-56. doi:
10.1111/j.1742-1241.2012.02911.x. [PMID: 22413962] - Sarah L Anderson, Joel C Marrs. Dapagliflozin for the treatment of type 2 diabetes.
The Annals of pharmacotherapy.
2012 Apr; 46(4):590-8. doi:
10.1345/aph.1q538. [PMID: 22433611] - John P H Wilding, Vincent Woo, Norman G Soler, Andrea Pahor, Jennifer Sugg, Katja Rohwedder, Shamik Parikh. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Annals of internal medicine.
2012 Mar; 156(6):405-15. doi:
10.7326/0003-4819-156-6-201203200-00003. [PMID: 22431673] - Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
The Journal of clinical endocrinology and metabolism.
2012 Mar; 97(3):1020-31. doi:
10.1210/jc.2011-2260. [PMID: 22238392] - Sreeneeranj Kasichayanula, Ming Chang, Xiaoni Liu, Wen-Chyi Shyu, Steven C Griffen, Frank P LaCreta, David W Boulton. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
Advances in therapy.
2012 Feb; 29(2):163-77. doi:
10.1007/s12325-011-0098-x. [PMID: 22271159] - Charles S Hummel, Chuan Lu, Jie Liu, Chiari Ghezzi, Bruce A Hirayama, Donald D F Loo, Vladimir Kepe, Jorge R Barrio, Ernest M Wright. Structural selectivity of human SGLT inhibitors.
American journal of physiology. Cell physiology.
2012 Jan; 302(2):C373-82. doi:
10.1152/ajpcell.00328.2011. [PMID: 21940664] - Niren K Shah, Wasim E Deeb, Rushab Choksi, Benjamin J Epstein. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Pharmacotherapy.
2012 Jan; 32(1):80-94. doi:
10.1002/phar.1010. [PMID: 22392830] - Scott C Thomson, Timo Rieg, Cynthia Miracle, Hadi Mansoury, Jean Whaley, Volker Vallon, Prabhleen Singh. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.
American journal of physiology. Regulatory, integrative and comparative physiology.
2012 Jan; 302(1):R75-83. doi:
10.1152/ajpregu.00357.2011. [PMID: 21940401] - John E Gerich, Arnaud Bastien. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
Expert review of clinical pharmacology.
2011 Nov; 4(6):669-83. doi:
10.1586/ecp.11.54. [PMID: 22111852] - K Strojek, K H Yoon, V Hruba, M Elze, A M Langkilde, S Parikh. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
Diabetes, obesity & metabolism.
2011 Oct; 13(10):928-38. doi:
10.1111/j.1463-1326.2011.01434.x. [PMID: 21672123] - A J Scheen, R P Radermecker, P Ernest, B J Jandrain. [Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes].
Revue medicale suisse.
2011 Aug; 7(306):1621-4, 1626. doi:
NULL. [PMID: 21972728] - S Kasichayanula, X Liu, W Zhang, M Pfister, S B Reele, A-F Aubry, F P LaCreta, D W Boulton. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.
Diabetes, obesity & metabolism.
2011 Aug; 13(8):770-3. doi:
10.1111/j.1463-1326.2011.01397.x. [PMID: 21435141] - S Kasichayanula, M Chang, M Hasegawa, X Liu, N Yamahira, F P LaCreta, Y Imai, D W Boulton. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Diabetes, obesity & metabolism.
2011 Apr; 13(4):357-65. doi:
10.1111/j.1463-1326.2011.01359.x. [PMID: 21226818] - Edward C Chao. A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Discovery medicine.
2011 Mar; 11(58):255-63. doi:
NULL. [PMID: 21447284] - S Kasichayanula, X Liu, W C Shyu, W Zhang, M Pfister, S C Griffen, T Li, F P LaCreta, D W Boulton. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Diabetes, obesity & metabolism.
2011 Jan; 13(1):47-54. doi:
10.1111/j.1463-1326.2010.01314.x. [PMID: 21114603] - Niki Katsiki, Nikolaos Papanas, Dimitri P Mikhailidis. Dapagliflozin: more than just another oral glucose-lowering agent?.
Expert opinion on investigational drugs.
2010 Dec; 19(12):1581-9. doi:
10.1517/13543784.2011.539558. [PMID: 21105857] - Wen-Bin Zhang, Nian Gong, Yong-Xiang Wang. [Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].
Sheng li ke xue jin zhan [Progress in physiology].
2010 Dec; 41(6):453-6. doi:
NULL. [PMID: 21416966] - Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Diabetes care.
2010 Oct; 33(10):2217-24. doi:
10.2337/dc10-0612. [PMID: 20566676] - Volker Vallon, Kumar Sharma. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
Current opinion in nephrology and hypertension.
2010 Sep; 19(5):425-31. doi:
10.1097/mnh.0b013e32833bec06. [PMID: 20539226] - L Zhang, Y Feng, J List, S Kasichayanula, M Pfister. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
Diabetes, obesity & metabolism.
2010 Jun; 12(6):510-6. doi:
10.1111/j.1463-1326.2010.01216.x. [PMID: 20518806] - Joshua J Neumiller, John R White, R Keith Campbell. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Drugs.
2010 Mar; 70(4):377-85. doi:
10.2165/11318680-000000000-00000. [PMID: 20205482] - M Obermeier, M Yao, A Khanna, B Koplowitz, M Zhu, W Li, B Komoroski, S Kasichayanula, L Discenza, W Washburn, W Meng, B A Ellsworth, J M Whaley, W G Humphreys. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Drug metabolism and disposition: the biological fate of chemicals.
2010 Mar; 38(3):405-14. doi:
10.1124/dmd.109.029165. [PMID: 19996149] - G Pérez López, O González Albarrán, M Cano Megías. [Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
2010; 30(6):618-25. doi:
10.3265/nefrologia.pre2010.sep.10494. [PMID: 21113210] - John P H Wilding, Paul Norwood, Caroline T'joen, Arnaud Bastien, James F List, Fred T Fiedorek. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.
Diabetes care.
2009 Sep; 32(9):1656-62. doi:
10.2337/dc09-0517. [PMID: 19528367] - Amie McCord Brooks, Stacey M Thacker. Dapagliflozin for the treatment of type 2 diabetes.
The Annals of pharmacotherapy.
2009 Jul; 43(7):1286-93. doi:
10.1345/aph.1m212. [PMID: 19584379] - B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, M Pfister. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Clinical pharmacology and therapeutics.
2009 May; 85(5):520-6. doi:
10.1038/clpt.2008.251. [PMID: 19129748] - B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Clinical pharmacology and therapeutics.
2009 May; 85(5):513-9. doi:
10.1038/clpt.2008.250. [PMID: 19129749] - James F List, Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Diabetes care.
2009 Apr; 32(4):650-7. doi:
10.2337/dc08-1863. [PMID: 19114612] - Mark Kipnes. Dapagliflozin: an emerging treatment option in type 2 diabetes.
Expert opinion on investigational drugs.
2009 Mar; 18(3):327-34. doi:
10.1517/13543780902766794. [PMID: 19243283] - Iskandar Idris, Richard Donnelly. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
Diabetes, obesity & metabolism.
2009 Feb; 11(2):79-88. doi:
10.1111/j.1463-1326.2008.00982.x. [PMID: 19125776] - S A Jabbour, B J Goldstein. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
International journal of clinical practice.
2008 Aug; 62(8):1279-84. doi:
10.1111/j.1742-1241.2008.01829.x. [PMID: 18705823] - Songping Han, Deborah L Hagan, Joseph R Taylor, Li Xin, Wei Meng, Scott A Biller, John R Wetterau, William N Washburn, Jean M Whaley. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Diabetes.
2008 Jun; 57(6):1723-9. doi:
10.2337/db07-1472. [PMID: 18356408] - Wei Meng, Bruce A Ellsworth, Alexandra A Nirschl, Peggy J McCann, Manorama Patel, Ravindar N Girotra, Gang Wu, Philip M Sher, Eamonn P Morrison, Scott A Biller, Robert Zahler, Prashant P Deshpande, Annie Pullockaran, Deborah L Hagan, Nathan Morgan, Joseph R Taylor, Mary T Obermeier, William G Humphreys, Ashish Khanna, Lorell Discenza, James G Robertson, Aiying Wang, Songping Han, John R Wetterau, Evan B Janovitz, Oliver P Flint, Jean M Whaley, William N Washburn. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Journal of medicinal chemistry.
2008 Mar; 51(5):1145-9. doi:
10.1021/jm701272q. [PMID: 18260618]
